A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer

Wenhui WANG; Xuhua DUAN; Hao LI; Shuguang JU; Manzhou WANG; Jianzhuang REN; Xinwei HAN

doi:10.3969/j.issn.1001-5256.2021.09.024

Volume 37 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(9): 2125-2129

PDF( 2198 KB)

A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer

DOI: 10.3969/j.issn.1001-5256.2021.09.024

Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

Research funding:

China foundation for the promotion of health (XM_2018_011_0006_01);

Key R&D and Promotion Special Project (Science and Technology Research) of Henan Province (202102310462)

Received Date: 2021-01-21
Accepted Date: 2021-02-08
Published Date: 2021-09-20

Abstract

Abstract

Objective To investigate the cost-effect of transarterial chemoembolization (TACE) with CalliSpheres beads loaded with arsenic trioxide (ATO) (CBATO) versus ATO iodized oil emulsion (conventional TACE, cTACE) in the treatment of unresectable liver cancer. Methods A total of 100 patients with advanced liver cancer who attended The First Affiliated Hospital of Zhengzhou University from May 2017 to December 2018 were enrolled and divided into CBATO group(n=45) and cTACE group(n=55) according to the treatment regimen. Progression-free survival (PFS) was used to evaluate the efficacy of quality-adjusted life year (QALY), and European Quality of Life-5 Dimensions (EQ-5D) index was used to evaluate quality of life. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups; the number of surgeries, length of hospital stay, treatment cost, and incremental cost-effectiveness ratio (ICER) were calculated for the two groups, and then a cost-effect analysis was performed. Results Within the PFS time, the per capita hospital cost was 96 446 yuan in the CBATO group and 91 230.43 yuan in the cTACE group. There were significant differences between the two groups in the mean number of surgeries (2.5±0.7 vs 3.4±0.8, t=16.911, P < 0.01) and mean hospital stay (5.8±1.2 days vs 7.5±1.8 days, t=12.459, P < 0.01). The CBATO group had a significantly higher QALY than the cTACE group (0.804 vs 0.512). Compared with the cTACE group, the CBATO group had an ICER of 17 861.53 yuan/QALY for unresectable liver cancer. Conclusion Although CBATO has a higher surgery cost than cTACE, CBATO has a better clinical effect than cTACE and can reduce the number of surgeries and length of hospital stay, with a better postoperative quality of life than cTACE, suggesting that CBATO has marked cost-effect advantages.
- Liver Neoplasms,
- Chemoembolization, Therapeutic,
- Microspheres,
- Iodized Oil,
- Cost-Benefit Analysis

FullText(HTML)

References(20)

References

[1]	LAI CL, RATZIU V, YUEN MF, et al. Viral hepatitis B[J]. Lancet, 2003, 362(9401): 2089-2094. DOI: 10.1016/S0140-6736(03)15108-2.
[2]	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[3]	AKO S, NAKAMURA S, NOUSO K, et al. Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation[J]. Acta Med Okayama, 2018, 72(1): 47-52. DOI: 10.18926/AMO/55662.
[4]	SONG MJ, CHUN HJ, SONG DS, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma[J]. J Hepatol, 2012, 57(6): 1244-1250. DOI: 10.1016/j.jhep.2012.07.017.
[5]	FACCIORUSSO A, DI MASO M, MUSCATIELLO N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis[J]. Dig Liver Dis, 2016, 48(6): 571-577. DOI: 10.1016/j.dld.2016.02.005.
[6]	PESAPANE F, NEZAMI N, PATELLA F, et al. New concepts in embolotherapy of HCC[J]. Med Oncol, 2017, 34(4): 58. DOI: 10.1007/s12032-017-0917-2.
[7]	National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
[8]	DUAN XH, JU SG, HAN XW, et al. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients[J]. Eur Rev Med Pharmacol Sci, 2020, 24(3): 1468-1480. DOI: 10.26355/eurrev_202002_20206.
[9]	FISMAN DN, TUITE AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada[J]. PLoS One, 2011, 6(11): e27420. DOI: 10.1371/journal.pone.0027420.
[10]	NEUMANN PJ, SANDERS GD. Cost-effectiveness analysis 2.0[J]. N Engl J Med, 2017, 376(3): 203-205. DOI: 10.1056/NEJMp1612619.
[11]	YIN WL, LIAN J, XIAO SX, et al. Clinical effect of drug-eluting beads and conventional transcatheter arterial chemoembolization in treatment of unresectable liver cancer: A meta-analysis[J]. J Clin Hepatol, 2019, 35(6): 1270-1275. DOI: 10.3969/j.issn.1001-5256.2019.06.018. 尹伟利, 连佳, 肖时湘, 等. 载药微球与传统碘化油经肝动脉化疗栓塞术治疗不可切除肝癌效果比较的Meta分析[J]. 临床肝胆病杂志, 2019, 35(6): 1270-1275. DOI: 10.3969/j.issn.1001-5256.2019.06.018.
[12]	FORNER A, GILABERT M, BRUIX J, et al. Treatment of intermediate-stage hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2014, 11(9): 525-535. DOI: 10.1038/nrclinonc.2014.122.
[13]	MELCHIORRE F, PATELLA F, PESCATORI L, et al. DEB-TACE: A standard review[J]. Future Oncol, 2018, 14(28): 2969-2984. DOI: 10.2217/fon-2018-0136.
[14]	MALAGARI K, POMONI M, MOSCHOURIS H, et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study[J]. Cardiovasc Intervent Radiol, 2014, 37(1): 165-175. DOI: 10.1007/s00270-013-0777-x.
[15]	CHEN MS, HU ZL. Research progress of hepatic arterial infusion chemotherapy in the conversion therapy of hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 171-177. DOI: 10.3760/cma.j.cn115610-20201230-00813. 陈敏山, 胡自力. 肝动脉灌注化疗在肝癌转化治疗中的研究进展[J]. 中华消化外科杂志, 2021, 20(2): 171-177. DOI: 10.3760/cma.j.cn115610-20201230-00813.
[16]	TRAN BX, OHINMAA A, NGUYEN LT. Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients[J]. Health Qual Life Outcomes, 2012, 10: 132. DOI: 10.1186/1477-7525-10-132.
[17]	XING M, WEBBER G, PRAJAPATI HJ, et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study[J]. J Gastroenterol Hepatol, 2015, 30(7): 1167-1174. DOI: 10.1111/jgh.12920.
[18]	LIU YS, OU MC, TSAI YS, et al. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma[J]. Korean J Radiol, 2015, 16(1): 125-132. DOI: 10.3348/kjr.2015.16.1.125.
[19]	ZHU D, YUAN D, WANG Z, et al. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients[J]. Medicine (Baltimore), 2019, 98(26): e15682. DOI: 10.1097/MD.0000000000015682.
[20]	KIMURA H, WEISZ A, KURASHIMA Y, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide[J]. Blood, 2000, 95(1): 189-197.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	苗晓飞，王洪剑. 载药微球化疗栓塞术治疗中晚期肝癌患者疗效及对血清GGT、钙磷代谢的影响. 肝脏. 2024(03): 300-302+312 .
2.	王明玉. 载药微球肝动脉化疗栓塞术与碘油肝动脉化疗栓塞术治疗不可切除肝癌的效果比较. 实用临床医学. 2024(03): 14-17 .
3.	朱新悦，袁一超，许杭俊，郑杭生，朱志红. 不同剂型三氧化二砷增效减毒作用的研究进展. 中草药. 2023(08): 2698-2704 .
4.	张涛，刘跃军，林文贤，陈泓霖. 洛铂与吡柔比星载药微球肝动脉栓塞化疗治疗不可切除肝癌的疗效对比. 吉林医学. 2023(10): 2908-2910 .
5.	耿冀洲，杨小斌. 载药微球肝动脉化疗栓塞术治疗大肝癌的临床效果及安全性. 临床医学研究与实践. 2022(21): 67-70 .
6.	张贻庆，崔贵医，杨磊，刘刚，冯世杰，王劲. 肝肿瘤切除术与射频消融术治疗原发性肝癌的疗效及其对血清AFP、CEA、CA125水平的影响. 实用癌症杂志. 2022(08): 1316-1319 .
7.	代树本，李海霞，王秀香，李辉. 载药微球联合肝动脉化疗栓塞术对原发性肝癌患者的疗效观察. 国际检验医学杂志. 2022(22): 2759-2762 .
8.	张剑，黄永东，毛健. 载药微球介入栓塞治疗对原发性肝癌的应用价值分析. 世界复合医学. 2022(12): 150-153 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (737) PDF downloads(60)

A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer

DOI: 10.3969/j.issn.1001-5256.2021.09.024